Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GLP-1 Injection-Site Amyloidosis Case

A 2026 case report describes a rare abdominal amyloid deposit after use of three injectable incretin medicines, with liraglutide detected at low levels.

Why we wrote this. The case adds a rare injection-site diagnosis to the GLP-1 literature while leaving the responsible medicine and frequency unresolved.

In this article (4 sections)
  1. What the biopsy and protein tests found
  2. An earlier liraglutide case sharpened the diagnosis
  3. What this single case does not establish
  4. What we still need to learn

A case report published online on October 30, 2026 describes a 71-year-old woman with a subcutaneous abdominal mass after prior use of liraglutide, semaglutide and tirzepatide. Congo red staining supported amyloid, while laboratory analysis found low spectral evidence for liraglutide and an antibody stain for glucagon marked the deposits. The authors classified the finding as localized GLP-1 analog-type amyloidosis[1]. A report about one patient can identify a rare diagnostic possibility. It cannot estimate how often the condition occurs or assign equal suspicion to every medicine in her treatment history.

What the biopsy and protein tests found

Amyloidosis is a group of conditions defined by extracellular deposits of insoluble proteins. In this case, the deposit was localized to subcutaneous tissue at an abdominal injection area. The biopsy included Congo red staining, a standard histologic method used to support the presence of amyloid. Liquid chromatography tandem mass spectrometry produced a typical amyloid protein profile and detected low spectra for liraglutide[1]. Low spectral evidence is not the same as an abundant, uniquely identified drug signal.

The investigators added immunohistochemistry after the mass spectrometry result. The deposits stained positive for glucagon, and the report notes extensive peptide sequence homology between glucagon and liraglutide[1]. Taken together, the pathology supported an amyloid deposit related to a GLP-1 analog-type peptide. The abstract does not report a unique semaglutide or tirzepatide peptide in the mass, so the patient's exposure history alone does not show that either of those medicines formed the deposit.

The authors describe the condition as iatrogenic and localized to GLP-1 analog injection areas. They also report only three previously published cases[1]. One of those later papers was explicitly titled as a second case of liraglutide-type localized amyloidosis[3]. That small publication record supports the word rare in the literature. It does not provide a population denominator, active surveillance or a risk estimate for people receiving injectable incretin medicines.

An earlier liraglutide case sharpened the diagnosis

The first detailed report appeared in 2018. An 81-year-old man had amyloid discovered in abdominal subcutaneous tissue during melanoma surgery. He used subcutaneous liraglutide for diabetes and also had an IgM lambda monoclonal gammopathy, which raised concern about systemic light-chain amyloidosis. Congo red staining confirmed extensive amyloid in the deep dermis and subcutis, while initial tests for light-chain and insulin-associated amyloid were negative[2].

Researchers then analyzed microdissected deposits by liquid chromatography mass spectrometry. They detected a peptide unique to liraglutide and another peptide shared by liraglutide, GLP-1 and glucagon. A peptide unique to native GLP-1 was absent. The team did not detect liraglutide or GLP-1 peptides in eight comparison amyloid samples, and the patient's deposit stained strongly with an anti-glucagon antibody[2]. Those converging findings gave the earlier report a more specific molecular link to liraglutide than exposure history alone could provide.

That 2018 team called the lesion the first reported case of liraglutide-induced amyloidosis. They warned that localized pharmaceutical amyloid can resemble systemic light-chain disease, especially when a patient also has a monoclonal protein or diabetes-related complications. Their concern was practical: systemic light-chain amyloidosis can lead to chemotherapy or stem cell transplantation, while the localized iatrogenic deposit described in their patient did not require those systemic treatments[2]. The new report repeats the concern that a local deposit could be misclassified as systemic amyloidosis, with different treatment and prognosis[1].

What this single case does not establish

The publication format sets firm limits. There was no comparison group, prospective follow-up cohort or denominator of exposed patients. The report cannot calculate incidence, compare products or identify personal risk factors. It also cannot show that GLP-1 medicines cause systemic amyloidosis. The lesion described in the abstract was a localized subcutaneous mass at an injection area, and the molecular testing centered on the material in that mass.

The three-drug history also needs careful handling. Prior exposure to liraglutide, semaglutide and tirzepatide was documented, but the protein work reported low spectra for liraglutide and glucagon-positive staining[1]. The abstract does not state that all three drugs were injected into exactly the same spot, give a full exposure timeline for each medicine or identify semaglutide-derived or tirzepatide-derived protein in the deposit. Assigning the lesion to the newest drug, the longest-used drug or the whole class would go beyond the reported evidence.

Nor does the case establish a symptom checklist that readers can use for self-diagnosis. A subcutaneous lump has many possible explanations, and Congo red staining plus protein typing required tissue and specialist laboratory methods in these reports. The evidence supports clinical awareness and accurate pathology work when amyloid is found near an injection area. It does not support stopping or changing prescribed treatment without an individual medical assessment.

What we still need to learn

Useful next evidence would include full clinical timelines, mapped injection sites, drug-specific peptide identification and follow-up after the affected area is no longer used. A case series could show whether the lesions share a consistent appearance or exposure pattern. A registry or denominator-based study would be needed to estimate frequency. None of those data are available from a four-case literature base.

For now, the strongest conclusion is narrow. The 2026 biopsy added another localized GLP-1 analog-type amyloid deposit to the medical literature, and its testing pointed toward liraglutide-related material without establishing the role of every prior medicine[1]. The earlier molecularly typed liraglutide case shows why pathologists may need to distinguish an injected peptide deposit from systemic light-chain amyloid[2]. Readers looking for the broader evidence on the two newer medicines can use our semaglutide research overview and tirzepatide evidence page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What is GLP-1 analog-type amyloidosis?

It is a rare localized deposit of amyloid protein reported in subcutaneous tissue at sites used for injected GLP-1 analog medicines. The 2026 paper found only three earlier reports, so its frequency is unknown.

Did semaglutide or tirzepatide cause the reported mass?

The patient had used both medicines as well as liraglutide, but the abstract reported low spectral evidence for liraglutide and glucagon-positive staining. It did not identify semaglutide-derived or tirzepatide-derived protein in the deposit.

Does an injection-site lump mean amyloidosis?

No. A lump can have many causes. The published cases required biopsy, Congo red staining and specialized protein analysis, so appearance or treatment history alone cannot establish this diagnosis.

Sources

  1. [1]Loggie J, McKay RC, Nasr SH, Stueck A. Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature. American Journal of Dermatopathology. 2026. PMID 42961329.Tier 1 · primary↩
  2. [2]Martins CO, Lezcano C, Yi SS, et al. Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. Haematologica. 2018. PMID 30262557.Tier 1 · primary↩
  3. [3]Muhammad S, McPhail ED, Tobin WO, et al. A second case of liraglutide-type localised amyloidosis. Amyloid. 2023. PMID 36476295.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars